AI GRAND ROUNDS

Authors: GEMINI (RESIDENT), GROK (ATTENDING), KIMI (EXPERT) & ANUPAM SINGH MD (Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

User:

Stage 1: History & Presentation (Timestamp: 3 Weeks Prior to Admission)
A 30-year-old male mechanic (residing in Delhi NCR, no prior renal disease, taking Adderall for ADHD and occasional Naproxen) presents with 3 weeks of progressive swelling, severe fatigue, and oliguria following a mild upper respiratory tract infection.
HPI:
- 3 Weeks Ago: Mild URI symptoms (sore throat, dry cough, low-grade fever). Over the following week, developed progressive lower extremity edema and new-onset hypertension. Presented to an outside hospital with serum creatinine 2.87 mg/dL and proteinuria; treated with oral diuretics and labetalol.
- 1 Week Prior: Rapidly increasing abdominal girth, severe facial and leg edema, and weight gain of +61 lbs (from 270 lbs to 331 lbs). Represented to emergency department with serum creatinine 3.88 mg/dL, BUN 85 mg/dL, K+ 6.0 mEq/L, and 3+ proteinuria.
- Presumed RPGN: Received empiric pulse IV Methylprednisolone (250 mg x 3 doses) and was transferred to tertiary care.

Resident:

Hello, Chief Resident here.

Key Findings:
* 30-year-old male with rapid-onset AKI (Creatinine 2.87 → 3.88 mg/dL) following a URI.
* Marked nephrotic/nephritic syndrome: severe edema (+61 lbs), hypertension, oliguria, hyperkalemia (6.0 mEq/L), and 3+ proteinuria.
* History of Naproxen use.

Differential Diagnoses:
1. IgA Nephropathy / Post-Infectious GN (35%): Post-URI presentation, rapid renal decline, and nephritic/nephrotic picture.
2. ANCA-Associated Vasculitis or Anti-GBM Disease (30%): Primary etiologies for Rapidly Progressive Glomerulonephritis (RPGN) with crescentic involvement.
3. Lupus Nephritis or Secondary Immune-Complex GN (20%): Can present as RPGN triggered by infection or underlying systemic autoimmune process.
4. NSAID-Induced Acute Interstitial Nephritis (AIN) with Minimal Change Disease (15%): Associated with Naproxen, explaining profound edema and proteinuria, though typically less aggressive.

Recommended Prioritized Tests:
1. Urgent Urgent Renal Biopsy: Gold standard to evaluate for crescents, immune deposits, and direct immunosuppressive strategy.
2. Serologic Panel: ANCA (PR3/MPO), Anti-GBM antibodies, ANA, C3, and C4 complement levels.
3. Urine Sediment Microscopy: Check for dysmorphic RBCs, dysmorphic red cell casts, and spot urine protein-to-creatinine ratio (UPCR).
4. Infectious Serologies: ASO, Anti-DNase B, HBV, HCV, and HIV.

Attending:

Hello Attending Consultant here

Critique: Solid prioritization of biopsy and serologies, but underweights drug exposures (Adderall vasoconstriction + Naproxen AIN/MCD overlap) and overcalls primary vasculitis without pulmonary-renal clues. Empiric steroids pre-biopsy risk masking histology; no mention of volume status optimization or dialysis thresholds amid oliguria/hyperK.

Top 3 DDx:
1. Post-infectious GN (IgA-dominant or infection-related) post-URI
2. NSAID-induced MCD/AIN with AKI
3. ANCA/anti-GBM crescentic GN

5 Specific Points:
1. Hold Adderall/NSAIDs; quantify cumulative Naproxen dose.
2. Add SPEP/UPEP, PLA2R Ab, anti-streptolysin titers pre-biopsy.
3. Urgent urine microscopy + UPCR; assess for active sediment.
4. Echo + albumin to quantify nephrotic contribution vs. cardiorenal.
5. Dialysis readiness (K 6.0, oliguria, +61 lb); delay further steroids pending biopsy.
6. Complement levels + cryos to refine immune-complex vs. pauci-immune.

Expert:

Hello, Expert Clinician here.

Best Unifying Dx: Infection-related GN (IgA-dominant post-infectious GN) with RPGN/crescents; fits post-URI, nephritic/nephrotic AKI.
Top Differentials & Fit:
- IgA-dominant PIGN (strongest): post-URI, C3 low, crescents.
- ANCA/anti-GBM RPGN: no systemic clues, but exclude.
- NSAID MCD/AIN: nephrosis + AKI, but HTN/oliguria less typical.
Key Pivot: Synpharyngitic URI → rapid AKI with nephrotic-range edema favors immune-complex GN over isolated AIN.
Next Move: Urgent renal biopsy + full serologies (ANCA, anti-GBM, C3/C4, ASO); avoid further steroids until tissue.
Pearl: Don’t let empiric pulse steroids precede biopsy in RPGN—tissue changes management and prevents misclassification.

Round 2

User:

Stage 2: Physical Examination & Initial Evaluation (Timestamp: Admission / Day 1)
Physical Exam: T 36.8°C (afebrile), HR 85 bpm, BP 162/80 mmHg, RR 18/min, SpO2 95% room air. Weight 331 lbs (+61 lbs above baseline).
Physical Findings: Marked bilateral lower extremity edema (3+ to hips), abdominal distension with flank dullness (ascites), abdominal striae, elevated JVP (10 cm H2O), dullness at lung bases.
Initial Laboratory Evaluation:
- Renal & Electrolytes: Serum Creatinine 3.9 mg/dL (rising to 6.5 mg/dL), BUN 151 mg/dL, Na 133, K 5.4, Bicarb 15 mEq/L, Anion gap 22.
- Proteins & Liver: Total Protein 5.3 g/dL, Serum Albumin 2.2 g/dL (severe hypoalbuminemia), ALT 40 U/L, AST 69 U/L, Alk Phos 299 U/L.
- Urinalysis: 1+ to 3+ protein, 5–10 RBCs/hpf, 3–5 WBCs/hpf, hyaline and waxy casts. No dysmorphic RBCs or RBC casts. Spot urine protein-to-creatinine ratio 0.23 g/g (measured post-diuresis/steroids).
- Hemogram: WBC 8.89 x 10³/µL, Hb 12.7 g/dL, Platelets 250,000/µL.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
* Severe, rapidly worsening AKI (Cr 3.9 → 6.5 mg/dL, BUN 151 mg/dL) with high anion gap metabolic acidosis (Bicarb 15).
* Massive fluid overload (+61 lbs), severe hypoalbuminemia (2.2 g/dL), ascites, elevated JVP.
* Unexpectedly low post-steroid UPCR (0.23 g/g) with waxy casts and non-dysmorphic RBCs.

Differential Diagnoses:
1. NSAID-Induced MCD / AIN with Superimposed ATN (40%): Naproxen exposure, severe hypoalbuminemia/edema, rapid drop in UPCR post-steroids, and relatively bland urine sediment.
2. Post-Infectious / IgA Glomerulonephritis (35%): Post-URI onset with RPGN course, though lack of active sediment is atypical.
3. Pauci-Immune / Anti-GBM RPGN (15%): Rapidly progressive renal failure; remains crucial to rule out despite bland sediment.
4. Ischemic ATN Secondary to Nephrotic Third-Spacing (10%): Intravascular depletion and severe hypervolemia driving acute tubular injury.

Prioritized Next Steps:
1. Urgent Renal Biopsy: Essential to differentiate ATN, interstitial nephritis, and crescentic disease.
2. Initiate Hemodialysis / Continuous Renal Replacement Therapy: Indicated for severe uremia (BUN 151), rapidly rising creatinine, and refractory volume overload.
3. Complete Serologic Workup: Send ANCA, Anti-GBM, C3/C4, ASO, and SPEP/UPEP.
4. Maintain Hold on NSAIDs and Adderall.

Attending:

Hello Attending Consultant here

Critique: Appropriate upweighting of NSAID-MCD/AIN given bland sediment + hypoalbuminemia, but over-relies on post-steroid/diuretic UPCR (unreliable); underemphasizes urgent RRT thresholds and ignores possible steroid-masked histology or concurrent ATN from third-spacing. Empiric steroids already given—hold further IS pending tissue.

Top 3 DDx:
1. NSAID-induced MCD ± AIN/ATN
2. Infection-related GN (IgA-dominant) with ATN overlay
3. Primary nephrotic (MCD/FSGS) + ischemic ATN

6 Specific Points:
1. Initiate HD now (BUN 151, Cr 6.5, acidosis, oliguria, +61 lb refractory overload).
2. Repeat UPCR/24h protein off peak diuresis; add FENa/urine eosinophils.
3. Urgent biopsy once stabilized—freeze for IF/EM.
4. TTE to exclude cardiomyopathy/pericardial effusion amid elevated JVP.
5. Full serologies + PLA2R, SPEP, ASO pre-biopsy; recheck complements.
6. Strict I/O, albumin + loop diuretic trial only if HD delayed; permanently discontinue Naproxen/Adderall.

Expert:

Hello, Expert Clinician here.

Best Unifying Dx: NSAID-induced MCD ± AIN with superimposed ischemic ATN (third-spacing from severe nephrosis).
Top Differentials & Fit:
- NSAID MCD/AIN + ATN (best): hypoalbuminemia, edema/ascites, falling UPCR post-steroids, bland sediment.
- Infection-related GN: post-URI, but waxy casts + low UPCR argue against.
- Primary FSGS/MCD + ATN: possible, but temporality and AKI favor drug effect.
Key Pivot: Post-diuresis/steroid UPCR 0.23 g/g despite massive edema → suggests recent nephrotic syndrome with ATN, not active RPGN.
Next Move: Start HD now for uremia/overload; biopsy after stabilization (before more steroids) with IF/EM.
Pearl: Treat the numbers, not the story—UPCR after diuresis/steroids can mislead; biopsy timing and RRT thresholds drive outcome.

Round 3

User:

Stage 3: Multi-Modal Serologic & Metabolic Diagnostic Workup (Timestamp: Hospital Days 1-3)
Diagnostic Workup:
- Autoimmune & Infectious Serologies: Complement C3 and C4 normal. ANA, ANCA (PR3/MPO), anti-GBM, Anti-dsDNA, Cryoglobulins, Hepatitis B/C, and HIV all negative. ASO positive (low/nonspecific).
- Metabolic & Vitamin Panel: Profoundly low Vitamin B12 (cobalamin <130 pg/mL) and severe hyperhomocysteinemia (homocysteine 26–100+ µmol/L).
- Hemolytic Screen: Peripheral blood smear shows no overt schistocytes (normocytic RBCs), LDH normal/mildly elevated, haptoglobin normal, ADAMTS13 activity 60% (normal).

Resident:

Hello, Chief Resident here.

Updated Key Findings:
* Negative RPGN Serologies: ANCA, Anti-GBM, ANA, Cryoglobulins negative; normal C3/C4.
* Negative TMA Screen: Normal ADAMTS13 (60%), no peripheral schistocytes.
* Critical Metabolic Abnormalities: Profound Vitamin B12 deficiency (<130 pg/mL) and severe hyperhomocysteinemia (26–100+ µmol/L).

Differential Diagnoses:
1. NSAID-Induced MCD / AIN with Ischemic ATN (50%): Best fits negative serologies, Naproxen trigger, severe hypoalbuminemia, and bland sediment.
2. Hyperhomocysteinemia / B12 Deficiency-Associated Renal TMA (25%): Severe hyperhomocysteinemia causes direct renal endothelial toxicity/microvascular thrombosis, potentially localized without overt systemic hemolysis.
3. IgA Nephropathy (15%): Post-URI onset with normal complement levels; cannot rule out without tissue.
4. Primary Podocytopathy (FSGS/MCD) with ATN (10%): Nephrotic syndrome leading to severe renal hypoperfusion.

Prioritized Next Steps:
1. Urgent Renal Biopsy: Vital to distinguish interstitial/podocyte pathology from localized TMA or IgAN.
2. Immediate B12 Therapy: Administer high-dose IV/IM Cyanocobalamin/Hydroxocobalamin plus folate.
3. Metabolic Evaluation: Order Methylmalonic Acid (MMA), anti-intrinsic factor, and anti-parietal cell antibodies.
4. Hemodialysis: Continue RRT for persistent uremia, acidosis, and volume management.

Attending:

Hello Attending Consultant here

Critique: Correctly pivots to negative serologies excluding classic RPGN/TMA, but overweights isolated renal TMA from hyperHcy (normal LDH/haptoglobin/ADAMTS13/smear argue against); under-explores B12 def as malnutrition marker in nephrosis or Adderall-related. Biopsy remains non-negotiable; empiric B12 wise but secondary.

Top 3 DDx:
1. NSAID-MCD ± AIN/ATN (bland sediment, hypoalbuminemia, drug exposure)
2. Primary podocytopathy (MCD/FSGS) + ischemic ATN
3. Hyperhomocysteinemia-mediated renal endothelial injury (B12-def driven)

6 Specific Points:
1. Immediate IM/IV B12 + folate; check MMA, anti-IF/parietal Abs, homocysteine trend.
2. Proceed to biopsy post-HD stabilization (light/IF/EM for TMA vs podocytopathy).
3. Repeat UPCR/24h protein; urine eosinophils/FENa for AIN/ATN.
4. Nutritional workup (folate, zinc, thiamine) + discontinue Adderall permanently.
5. Monitor for occult TMA (daily smear/LDH); hold further IS.
6. Echo + lipid panel to quantify nephrotic complications amid persistent overload.

Expert:

Hello, Expert Clinician here.

Best Unifying Dx: NSAID-associated nephrotic syndrome (MCD/AIN) with superimposed ischemic ATN; B12 deficiency likely incidental or secondary.
Top Differentials & Fit:
- NSAID-MCD/AIN + ATN (best): bland sediment, hypoalbuminemia, drug exposure, negative serologies.
- Primary MCD/FSGS + ATN: fits nephrosis/AKI, but NSAID timing favors drug cause.
- Hyperhomocysteinemia-related renal endothelial injury: possible, yet no systemic TMA features.
Key Pivot: Normal complements + negative autoimmune serologies + bland sediment push away from immune RPGN toward podocyte/ischemic injury.
Next Move: Start HD and obtain renal biopsy (light/IF/EM); initiate B12/folate repletion in parallel.
Pearl: When serologies are negative and urine is bland, think nephrotic syndrome with ATN—biopsy clarifies prognosis and steroid strategy.

Round 4

User:

Stage 4: Renal Biopsy & Histopathologic Findings (Timestamp: Hospital Days 3-5)
Percutaneous Renal Biopsy:
- Light Microscopy: Diffuse glomerular capillary loop narrowing with severe endothelial cell swelling ("endotheliosis"), thickening of capillary walls, acute tubular injury with cellular debris, and absence of significant interstitial inflammation, crescents, or hypercellularity.
- Immunofluorescence: Completely negative for IgG, IgA, IgM, C3, C1q, and light chains. Positive for fibrillar fibrin deposition along endothelial surfaces.
- Electron Microscopy: Widespread, dramatic subendothelial widening of the lamina rara interna, endothelial cell detachment, capillary loop wrinkling, and acute endothelial remodeling.
- Pathology Unifying Diagnosis: Renal-Limited Thrombotic Microangiopathy (TMA) / Endothelial Cell Injury secondary to Severe Hyperhomocysteinemia and Vitamin B12 (Cobalamin) Deficiency / Adult-Onset Cobalamin C (cblC) Defect.

Resident:

Hello, Chief Resident here.

Key Findings:
* Renal biopsy confirms pauci-immune Renal-Limited TMA: endotheliosis, severe subendothelial widening, and negative immunofluorescence (fibrin only).
* Pathology unifies presentation with severe hyperhomocysteinemia and profound B12 deficiency.

Differential Diagnoses:
1. Cobalamin C (cblC) Defect / B12 Deficiency-Induced Renal TMA (85%): Biopsy-proven TMA without immune complexes, directly caused by intracellular cobalamin pathway failure and extreme intracellular homocysteine toxicity.
2. Atypical Hemolytic Uremic Syndrome (aHUS) (10%): Complement-mediated TMA sharing histological features, but lacking complement deposition and secondary to a primary metabolic defect.
3. Drug-Induced TMA (5%): Adderall/Naproxen-triggered endothelial damage, potentially acting as a second hit on a metabolically vulnerable endothelium.

Prioritized Next Steps:
1. Targeted Metabolic Therapy: Immediately initiate high-dose parenteral Hydroxocobalamin (1–2 mg daily), Folinic Acid, and Betaine to lower toxic homocysteine levels.
2. Genetic Confirmation: Perform MMACHC gene sequencing to diagnose adult-onset Cobalamin C defect.
3. Metabolic Diagnostics: Send serum and urine Methylmalonic Acid (MMA) levels.
4. Renal Support: Continue Hemodialysis while awaiting metabolic recovery and endothelial repair.
5. Avoid Eculizumab/Immunosuppression: Discontinue steroids; complement blockades are unnecessary for this metabolic etiology.

Attending:

Hello Attending Consultant here

Critique: Excellent pivot to metabolic TMA post-biopsy; correctly de-emphasizes IS/eculizumab. Underweights acquired vs. genetic B12 etiologies and fails to address potential Adderall endothelial synergy or residual volume/uremic management. Genetic testing essential but do not delay empiric repletion.

Top 3 DDx:
1. Adult-onset cblC (MMACHC) defect with hyperHcy-TMA
2. Acquired severe B12 deficiency (pernicious/malnutrition) inducing renal-limited TMA
3. Drug-potentiated TMA (Adderall/NSAID) on metabolic background

6 Specific Points:
1. Start high-dose IV/IM hydroxocobalamin 1-2 mg daily + betaine/folinic acid immediately; trend Hcy/MMA.
2. Urgent MMACHC sequencing + plasma/urine MMA, anti-IF Abs.
3. Continue HD; reassess recovery of GFR/endothelial function q48h.
4. Permanently stop Adderall/NSAIDs; screen for other TMA triggers (complement genes if no response).
5. Hold all IS/steroids; no eculizumab indicated.
6. Echo + fundoscopy for systemic microangiopathy; nutritional repletion panel.

Expert:

Hello, Expert Clinician here.

Best Unifying Dx: Renal-limited TMA from severe hyperhomocysteinemia due to B12/cblC pathway defect (acquired vs inherited).
Top Differentials & Fit:
- cblC (MMACHC) defect: biopsy-consistent, high Hcy, no complement deposition.
- Acquired B12 deficiency–induced TMA: plausible, especially with low B12.
- aHUS: excluded by negative immune/complement findings and metabolic derangement.
Key Pivot: Biopsy showing TMA without immune deposits reframes “RPGN” as metabolic endothelial injury.
Next Move: Immediate hydroxocobalamin + betaine/folinic acid, continue HD, and obtain MMACHC genetics + MMA; stop steroids and avoid eculizumab.
Pearl: In TMA, normal ADAMTS13 and negative serologies do not exclude a treatable cause—B12/homocysteine can be the culprit.

Round 5

User:

Stage 5: High-Dose Metabolic Therapy & Clinical Recovery (Timestamp: Follow-up & Discharge)
Management & Outcome:
- Management Decision: Eculizumab and Plasma Exchange withheld (no systemic hemolysis or DIC).
- Targeted Metabolic Therapy: High-dose Parenteral Vitamin B12 (Cyanocobalamin 1000 mcg IM daily), Folate, Pyridoxine, and aggressive loop diuretic therapy.
- Clinical Outcome: Rapid diuresis with complete resolution of anasarca (-61 lbs weight loss), clearance of proteinuria, and dramatic recovery of renal function: Serum creatinine normalized from 6.5 mg/dL to 0.9 mg/dL at 4–6 weeks follow-up.

Resident:

Hello, Chief Resident here.

Key Findings:
* Dramatic clinical and renal recovery following high-dose parenteral B12, folate, and diuresis.
* Creatinine normalized (6.5 → 0.9 mg/dL) with complete resolution of proteinuria and anasarca (-61 lbs).
* Reversal without complement blockade or plasma exchange confirms metabolic etiology.

Final Diagnostic Probabilities:
1. Metabolic Renal-Limited TMA (cblC Defect / B12 Deficiency-Induced) (95%): Biopsy-proven pauci-immune TMA with complete renal reversal following targeted metabolic repletion.
2. Drug-Exaggerated Microvascular Injury (5%): Potential contributing role of Adderall/Naproxen as endothelial stressors on a metabolically compromised vascular bed.

Follow-Up & Management Plan:
1. Genetic Confirmation: Await MMACHC gene sequencing to differentiate adult-onset cblC defect from acquired B12 deficiency.
2. Maintenance Therapy: Maintain lifelong parenteral B12 supplementation; periodically monitor serum homocysteine and MMA levels to ensure metabolic control.
3. Outpatient Monitoring: Routine follow-up of serum creatinine, urine protein, and hematologic parameters.
4. Preventive Strategy: Permanent avoidance of NSAIDs/nephrotoxins; provide genetic counseling if MMACHC mutation is identified.

Attending:

Hello Attending Consultant here

Critique: Strong confirmation of metabolic etiology via steroid-free recovery, but under-explores acquired vs. genetic distinction and long-term relapse risk; omits family screening and residual endothelial monitoring. Cyanocobalamin suboptimal vs. hydroxocobalamin for cblC.

Top 3 DDx:
1. Adult-onset cblC (MMACHC) defect–induced renal TMA
2. Acquired B12 deficiency (pernicious/malabsorptive) with hyperHcy-TMA
3. Drug-potentiated (Adderall/NSAID) metabolic TMA

6 Specific Points:
1. Switch to high-dose hydroxocobalamin IM/IV; add betaine if Hcy persists.
2. Expedite MMACHC sequencing + anti-IF Abs/MMA to confirm etiology.
3. Lifelong B12; q3mo Hcy/MMA/Cr/UPCR surveillance.
4. Genetic counseling/family screening if pathogenic variant found.
5. Permanent NSAID/Adderall ban; avoid endothelial toxins.
6. Baseline Echo/fundoscopy; no eculizumab/PLEX needed.

Expert:

Hello, Expert Clinician here.

Best Unifying Dx: Renal-limited TMA due to hyperhomocysteinemia from B12/cblC pathway defect, reversed with metabolic therapy.
Top Differentials & Fit:
- cblC (MMACHC) defect: best fit given biopsy + response.
- Acquired B12 deficiency–TMA: possible, but less likely with this severity.
- Complement-mediated TMA: excluded by negative IF and clinical response without eculizumab.
Key Pivot: Biopsy + lack of immune deposits redirected from immunosuppression to metabolic rescue.
Next Move: Confirm with MMACHC genetics + MMA, continue hydroxocobalamin/betaine, and monitor homocysteine, renal function, and proteinuria; avoid NSAIDs/Adderall.
Pearl: A dramatic response to vitamins can be diagnostic—functional confirmation often rivals pathology.

Top 15 Takeaways for Clinicians

  1. Definition of Cobalamin-Mediated Renal TMA: Inborn errors of cobalamin metabolism (such as adult-onset Cobalamin C / cblC defect) or severe acquired Vitamin B12 deficiency can cause renal-limited thrombotic microangiopathy (TMA) driven by intracellular accumulation of homocysteine and methylmalonic acid (MMA).
  2. Mechanism of Endothelial Toxicity: Severe hyperhomocysteinemia (>100 µmol/L) exerts direct toxic oxidative stress on microvascular endothelial cells, inhibiting nitric oxide synthesis, triggering endothelial cell swelling (endotheliosis), and impairing capillary lumen patency.
  3. Renal-Limited Presentation Without Systemic Hemolysis: Cobalamin/homocysteine-mediated TMA can present as pure renal-limited endothelial dysfunction with acute kidney injury, severe anasarca, and heavy proteinuria WITHOUT systemic microangiopathic hemolytic anemia, thrombocytopenia, or peripheral blood schistocytes.
  4. Pitfall of Misdiagnosing Glomerulonephritis: The combination of post-URI onset, rapid AKI, severe edema, and 3+ proteinuria often leads clinicians to misdiagnose post-streptococcal GN or RPGN and administer unnecessary empiric pulse corticosteroids.
  5. Normal Complement Profile: Serum complement levels (C3 and C4) are characteristically normal, distinguishing metabolic TMA from complement-mediated atypical Hemolytic Uremic Syndrome (aHUS).
  6. Pathognomonic Electron Microscopy Finding: Renal biopsy electron microscopy reveals dramatic, widespread subendothelial widening of the lamina rara interna with endothelial cell detachment and capillary loop wrinkling, pathognomonic for severe endothelial injury.
  7. Negative Immunofluorescence: Immunofluorescence demonstrates an absence of immunoglobulins (IgG, IgA, IgM) and complement fractions (C3, C1q), with only endothelial fibrin deposition, excluding immune-complex glomerulonephritis.
  8. Inutility of Eculizumab and Plasma Exchange: Neither plasma exchange (PLEX) nor terminal complement inhibition (eculizumab) is effective for metabolic TMA, as the underlying defect is metabolic rather than antibody- or complement-mediated.
  9. Primary Targeted Metabolic Therapy: High-dose parenteral Vitamin B12 (Hydroxocobalamin 1–2 mg IM daily or Cyanocobalamin) is the essential disease-modifying treatment to bypass the metabolic block and lower homocysteine levels.
  10. Role of Adjunctive Remethylation Cofactors: Concomitant administration of Folate/Folinic Acid, Pyridoxine (Vitamin B6), and Betaine (anhydrous trimethylglycine) supports alternative homocysteine remethylation pathways and accelerates biochemical recovery.
  11. Potency of Renal Functional Recovery: Unlike ischemic or complement-mediated TMA where glomerular injury often leaves permanent sclerosis, metabolic renal TMA exhibits extraordinary potential for complete functional recovery (e.g. serum creatinine returning from 6.5 mg/dL to 0.9 mg/dL).
  12. Screening Requirement in Unexplained AKI: Screening for serum Vitamin B12 and plasma homocysteine should be part of the diagnostic evaluation for cryptogenic acute kidney injury with non-immune endothelial biopsy changes.
  13. Role of Environmental Second-Hits: Intercurrent viral infections, NSAID ingestion, or sympathetic stimulants (such as Adderall/amphetamines) can act as synergistic second-hits that precipitate acute endothelial decompensation in patients with baseline hyperhomocysteinemia.
  14. Genetic Evaluation in Young Adults: Young adults presenting with cobalamin-responsive TMA should undergo genetic sequencing for MMACHC gene mutations to confirm adult-onset Cobalamin C (cblC) deficiency.
  15. Avoidance of Nitrous Oxide & Nephrotoxins: Patients with cobalamin metabolism defects must strictly avoid nitrous oxide anesthesia (which irreversibly inactivates methionine synthase) and long-term NSAID therapy.